Kemeny N, Yagoda A, Braun D, Golbey R
Cancer. 1979 Jan;43(1):78-82. doi: 10.1002/1097-0142(197901)43:1<78::aid-cncr2820430111>3.0.co;2-h.
Sixty-seven patients with measurable colorectal carcinoma were randomized to receive two different schedules of Methyl CCNU, 5-FU and Vincristine (MOF). The treatment schedule consisted of Methyl CCNU 150 mg/m2 po q 70 days, 5-FU 300 mg/m2 iv for 5 consecutive days q 35 days, and Vincristine 1 mg/m2 IV q 35 days. The same total dose was used in each arm; in MOF A, the Methyl CCNU was given on day 1, while in MOF B, the Methyl CCNU was divided and given over 5 consecutive days. In MOF A, there was a 10% partial response rate and a 10% minor response rate. In MOF B, the partial response rate was 12% and the minor response rate was 21%. This difference is not statistically significant, but the patients in MOF B experienced less gastrointestinal toxicity (p less than .001).
67例可测量的结肠直肠癌患者被随机分配接受两种不同方案的甲环亚硝脲、5-氟尿嘧啶和长春新碱（MOF）治疗。治疗方案包括：甲环亚硝脲150mg/m²口服，每70天一次；5-氟尿嘧啶300mg/m²静脉注射，连续5天，每35天一次；长春新碱1mg/m²静脉注射，每35天一次。每组使用相同的总剂量；在MOF A组中，甲环亚硝脲在第1天给药，而在MOF B组中，甲环亚硝脲分5天连续给药。在MOF A组中，部分缓解率为10%，轻度缓解率为10%。在MOF B组中，部分缓解率为12%，轻度缓解率为21%。这种差异无统计学意义，但MOF B组患者的胃肠道毒性较小（p<0.001）。
